Versameb to present novel data on its lead asset
04.11.2021
Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference...
News
Kinarus Secures CHF 57 Million Capital Commitment
14.09.2021
Kinarus AG, a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with...
TargImmune successfully closed its 2021 financing round
27.07.2021
TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on ...
Monte Rosa Therapeutics raises USD 222 million in successful IPO
29.06.2021
Monte Rosa Therapeutics, a US-Swiss biotech company focused on discovering and developing precision medicines that degrade disease-causing proteins, reached...
Alentis Therapeutics Raises USD 67 Million in Series B Financing
15.06.2021
Basel, Switzerland and Strasbourg, France, 15 June 2021 — Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round.